RITONAVIR ACCORD 100mg tablets medication leaflet

J05AE03 ritonavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Ritonavir is a protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for processing viral proteins and forming mature viral particles, thereby reducing viral replication in the body.

Ritonavir is administered orally, usually in combination with other antiretroviral medications, as part of highly active antiretroviral therapy (HAART). It is often used as a pharmacokinetic booster for other antiretroviral drugs, increasing their blood concentrations by inhibiting hepatic enzymes responsible for their metabolism.

Common side effects include nausea, diarrhea, fatigue, and elevated blood lipid levels. In rare cases, severe adverse reactions such as hepatotoxicity or pancreatitis may occur. Regular monitoring of liver function and metabolic parameters is essential.

Ritonavir is an important component of antiretroviral therapy, contributing to the effective management of HIV infection and improving patients' quality of life.

General data about RITONAVIR ACCORD 100mg

Substance: ritonavir

Date of last drug list: 01-03-2022

Commercial code: W63507001

Concentration: 100mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 9768/2017/01

Shelf life: 3 years-after packing for marketing;after the first opening of the bottle-it is used immediately

Pharmaceutical forms available for ritonavir

Concentrations available for ritonavir

100mg, 80mg/ml